KemPharm files IND for KP484 for treatment of ADHD
KemPharm announced it has filed an IND application with the FDA to begin human clinical trials of KP484, the Company’s prodrug product candidate of “super-extended” release d-methylphenidate (d-MPH) for treatment of attention deficit hyperactivity disorder. September 20, 2017